On November 30, 2016, pursuant to that certain amended and restated equity holders agreement, dated May 15, 2015 between, Mayne Pharma Ventures Pty Ltd., HedgePath Pharmaceuticals, Inc. and the other parties thereto. Removing Samuel P. Sears, Jr. as a director of the company and electing Robert D. Martin as a director of the company. Since 2006, Martin has been part of The Interlochen Group, LLC.